Host bacterial targets mediating immune suppression in pneumonic tularemia

宿主细菌靶标介导肺炎兔热病的免疫抑制

基本信息

  • 批准号:
    8233341
  • 负责人:
  • 金额:
    $ 60.46万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-03-01 至 2014-02-28
  • 项目状态:
    已结题

项目摘要

The most worrisome infectious agents of bioterrorism are those that would be artificially disseminated as aerosols to the lungs where the immune responses are unique, primarily driven by an immunoregulatory program. Critical mediators of the immune response in this environment are alveolar macrophages (AM) and epithelial cells. Francisella tularensis (Ft), a targeted infectious agent of bioterrorism, is an intracellular pathogen which causes acute life-threatening disease, particularly when transmitted via aerosols. The eukaryotic and microbial factors mediating host cell recognition and response for Ft remain poorly defined and their definition will be required for the rational development of new therapies and vaccines. This competitive renewal of RP9 unites an established group of collaborative scientists from the Ohio State University, Medical College of Wisconsin and University of Cincinnati to focus on the molecular pathogenesis of pneumonic tularemia. Based on recently published work and preliminary data, our central hypothesis is that Ft's success as a human pathogen is linked to its ability to suppress and/or subvert important elements of the protective innate immune response during the early phase of infection. To test this hypothesis we will 1) further define the molecular mechanisms that mediate Ft entry, intracellular trafficking, antimicrobial responses and initiation of the inflammatory program both in vitro and in vivo; 2) construct, validate, and probe global microbial and host genetic screening platforms to identify key determinants mediating Ftinduced immune suppression and/or subversion; and 3) use targeted genetic approaches to identify novel Ft virulence determinants focusing on bacterial transcriptional regulators and Ft and host factors involved in Fe metabolism, including those of the bacterial oxidative stress response. Collectively, these studies will provide important new insights into host-pathogen interactions by the most virulent Ft subspecies, and will use novel mutant derivatives and relevant model systems of infection. This RP will synergize the talents of its investigators to place itself in the most competitive position to make fundamental discoveries related to pathogenic mechanisms for Ft, and begin to translate these discoveries into product development.
生物恐怖主义最令人担忧的传染性病原体是那些人为传播的病原体, 气溶胶进入肺部,那里的免疫反应是独特的,主要是由免疫调节因子驱动的。 程序.在这种环境中,免疫反应的关键介质是肺泡巨噬细胞(AM) 和上皮细胞。土拉热弗朗西丝菌(Francisella tularensis,Ft)是一种生物恐怖主义的靶向感染因子, 导致急性危及生命的疾病的病原体,特别是通过气溶胶传播时。的 介导宿主细胞对Ft的识别和应答的真核和微生物因子仍然不清楚 并且它们的定义将是合理开发新疗法和疫苗所必需的。这 RP9的竞争性更新将来自俄亥俄州的一组合作科学家团结在一起 威斯康星州医学院和辛辛那提大学的合作,重点关注分子发病机制 肺性土拉菌病基于最近发表的工作和初步数据,我们的中心假设是 Ft作为人类病原体的成功与其抑制和/或破坏重要元素的能力有关 在感染的早期阶段保护性的先天免疫反应。为了验证这个假设,我们将 1)进一步确定介导Ft进入、细胞内运输、抗微生物 反应和启动炎症程序的体外和体内; 2)构建,验证, 探索全球微生物和宿主遗传筛选平台,以确定介导Ft诱导的关键决定因素 免疫抑制和/或破坏;和3)使用靶向遗传方法来鉴定新的Ft 毒力决定簇集中在细菌转录调节因子和Ft和宿主因子参与Fe 代谢,包括细菌氧化应激反应。这些研究将提供 重要的新见解宿主-病原体相互作用的最致命的Ft亚种,并将使用新的 感染的突变衍生物和相关模型系统。这RP将协同其人才 研究人员将自己置于最具竞争力的地位,使有关的基本发现, Ft的致病机制,并开始将这些发现转化为产品开发。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Larry S. Schlesinger其他文献

Mycobacterium tuberculosis remodels host transcriptome
结核分枝杆菌重塑宿主转录组
  • DOI:
    10.1038/s41564-021-01056-x
  • 发表时间:
    2022-01-31
  • 期刊:
  • 影响因子:
    19.400
  • 作者:
    Melanie A. Carless;Larry S. Schlesinger
  • 通讯作者:
    Larry S. Schlesinger
Identifying Mycobacterium tuberculosis virulence determinants - new technologies for a difficult problem.
识别结核分枝杆菌毒力决定因素——解决难题的新技术。
  • DOI:
  • 发表时间:
    2000
  • 期刊:
  • 影响因子:
    15.9
  • 作者:
    Lucy E. Desjardin;Larry S. Schlesinger
  • 通讯作者:
    Larry S. Schlesinger
Antibody-independent classical complement pathway activation by wildtype and LPS O-antigen mutant <em>Francisella tularensis</em> strains
  • DOI:
    10.1016/j.molimm.2010.05.146
  • 发表时间:
    2010-08-01
  • 期刊:
  • 影响因子:
  • 作者:
    Corey D. Clay;John S. Gunn;Larry S. Schlesinger
  • 通讯作者:
    Larry S. Schlesinger
Timing matters in macrophage/CD4+ T cell interactions: an agent-based model comparing emMycobacterium tuberculosis/em host-pathogen interactions between latently infected and naïve individuals
时机在巨噬细胞/CD4+T 细胞相互作用中很重要:一个基于代理的模型比较了潜伏感染和未感染个体之间的结核分枝杆菌宿主-病原体相互作用
  • DOI:
    10.1128/msystems.01290-24
  • 发表时间:
    2025-02-27
  • 期刊:
  • 影响因子:
    4.600
  • 作者:
    Alexis Hoerter;Alexa Petrucciani;Jordan Bonifacio;Eusondia Arnett;Larry S. Schlesinger;Elsje Pienaar
  • 通讯作者:
    Elsje Pienaar
Impact of the elderly lung mucosa on emMycobacterium tuberculosis/em transcriptional adaptation during infection of alveolar epithelial cells
老年肺黏膜对肺泡上皮细胞感染期间结核分枝杆菌转录适应性的影响
  • DOI:
    10.1128/spectrum.01790-24
  • 发表时间:
    2024-10-30
  • 期刊:
  • 影响因子:
    3.800
  • 作者:
    Angélica M. Olmo-Fontánez;Anna Allué-Guardia;Andreu Garcia-Vilanova;Jeremy Glenn;Shu-Hua Wang;Robert E. Merritt;Larry S. Schlesinger;Joanne Turner;Yufeng Wang;Jordi B. Torrelles
  • 通讯作者:
    Jordi B. Torrelles

Larry S. Schlesinger的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Larry S. Schlesinger', 18)}}的其他基金

Administrative Core
行政核心
  • 批准号:
    10431466
  • 财政年份:
    2022
  • 资助金额:
    $ 60.46万
  • 项目类别:
Interdisciplinary NexGen TB research Advancement Center (IN-TRAC)
跨学科 NexGen 结核病研究推进中心 (IN-TRAC)
  • 批准号:
    10588203
  • 财政年份:
    2022
  • 资助金额:
    $ 60.46万
  • 项目类别:
Clinical Research & Patient Care Core (CRPCC)
临床研究
  • 批准号:
    10431471
  • 财政年份:
    2022
  • 资助金额:
    $ 60.46万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10588204
  • 财政年份:
    2022
  • 资助金额:
    $ 60.46万
  • 项目类别:
Interdisciplinary NexGen TB research Advancement Center (IN-TRAC)
跨学科 NexGen 结核病研究推进中心 (IN-TRAC)
  • 批准号:
    10431465
  • 财政年份:
    2022
  • 资助金额:
    $ 60.46万
  • 项目类别:
Clinical Research & Patient Care Core (CRPCC)
临床研究
  • 批准号:
    10588232
  • 财政年份:
    2022
  • 资助金额:
    $ 60.46万
  • 项目类别:
Macrophage nuclear receptors, metabolism and immune effectors during health and M. tuberculosis infection
健康和结核分枝杆菌感染期间的巨噬细胞核受体、代谢和免疫效应器
  • 批准号:
    10450960
  • 财政年份:
    2020
  • 资助金额:
    $ 60.46万
  • 项目类别:
Macrophage nuclear receptors, metabolism and immune effectors during health and M. tuberculosis infection
健康和结核分枝杆菌感染期间的巨噬细胞核受体、代谢和免疫效应器
  • 批准号:
    10457308
  • 财政年份:
    2019
  • 资助金额:
    $ 60.46万
  • 项目类别:
Macrophage nuclear receptors, metabolism and immune effectors during health and M. tuberculosis infection- Diversity Supplement
健康和结核分枝杆菌感染期间的巨噬细胞核受体、代谢和免疫效应器 - Diversity Supplement
  • 批准号:
    10116937
  • 财政年份:
    2019
  • 资助金额:
    $ 60.46万
  • 项目类别:
Expansion of Marmoset Breeding Facilities to Meet Increasing Research Demands
扩建狨猴饲养设施以满足不断增长的研究需求
  • 批准号:
    9933536
  • 财政年份:
    2019
  • 资助金额:
    $ 60.46万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 60.46万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 60.46万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 60.46万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 60.46万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 60.46万
  • 项目类别:
    Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 60.46万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 60.46万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 60.46万
  • 项目类别:
    Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 60.46万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 60.46万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了